ATE154514T1 - Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix - Google Patents

Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix

Info

Publication number
ATE154514T1
ATE154514T1 AT90915863T AT90915863T ATE154514T1 AT E154514 T1 ATE154514 T1 AT E154514T1 AT 90915863 T AT90915863 T AT 90915863T AT 90915863 T AT90915863 T AT 90915863T AT E154514 T1 ATE154514 T1 AT E154514T1
Authority
AT
Austria
Prior art keywords
pathologies
growth factor
extracellular matrix
beta
transforming growth
Prior art date
Application number
AT90915863T
Other languages
English (en)
Inventor
Wayne A Border
Erkki I Ruoslahti
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of ATE154514T1 publication Critical patent/ATE154514T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hooks, Suction Cups, And Attachment By Adhesive Means (AREA)
  • Steroid Compounds (AREA)
AT90915863T 1989-09-29 1990-09-27 Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix ATE154514T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41508189A 1989-09-29 1989-09-29
US41665689A 1989-10-03 1989-10-03

Publications (1)

Publication Number Publication Date
ATE154514T1 true ATE154514T1 (de) 1997-07-15

Family

ID=27022856

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90915863T ATE154514T1 (de) 1989-09-29 1990-09-27 Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix

Country Status (10)

Country Link
EP (2) EP0775742A3 (de)
JP (1) JPH0780780B2 (de)
AT (1) ATE154514T1 (de)
AU (1) AU654938B2 (de)
CA (1) CA2065860C (de)
DE (1) DE69030956T2 (de)
DK (1) DK0494264T3 (de)
FI (1) FI921353L (de)
NO (1) NO921119D0 (de)
WO (1) WO1991004748A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
JP3854307B2 (ja) * 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019783A1 (en) * 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5395825A (en) * 1993-03-10 1995-03-07 Yale University Fertility regulation with transforming growth factor β
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
ATE315939T1 (de) * 1993-11-19 2006-02-15 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
JP4083794B2 (ja) * 1994-03-29 2008-04-30 レノボ・リミテッド 創傷の治癒
JP4531132B2 (ja) * 1995-06-02 2010-08-25 ギリード・サイエンシズ・インコーポレーテッド 増殖因子に対する高親和性オリゴヌクレオチドリガンド
GB2304045A (en) † 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU771635B2 (en) * 1999-01-05 2004-04-01 American National Red Cross, The Methods for treating conditions associated with the accumulation of excess extracellular matrix
AU2008200019B2 (en) * 1999-01-05 2009-10-08 American National Red Cross Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
JP4566605B2 (ja) * 2004-04-02 2010-10-20 有限会社開発顧問室 短鎖ペプチドを有効成分とするコラーゲン合成阻害剤およびその製造方法
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
AU2005320014B2 (en) 2004-12-22 2011-05-26 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
EP2230252A1 (de) 2006-03-13 2010-09-22 The Johns Hopkins University Erhöhung der endothelialen Thromboresistenz
EP2918288B1 (de) 2006-10-03 2017-08-16 Genzyme Corporation Verwendung von TGF-beta-Antagonisten zur Behandlung von Kleinkindern mit dem Risiko der Entwicklung von bronchopulmonaler Dysplasie
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CA2823154A1 (en) 2010-12-27 2012-07-05 Lsip, Llc Ips cells and method for generating same
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
BR112014009789A2 (pt) 2011-10-26 2017-04-25 Seattle Children's Res Inst cisteamina no tratamento da doença fibrótica
EP2799537B1 (de) 2011-12-28 2021-09-22 Kyoto Prefectural Public University Corporation Normalisierung der züchtung von hornhautendothelzellen
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
WO2015064768A1 (ja) 2013-10-31 2015-05-07 京都府公立大学法人 角膜内皮の小胞体細胞死関連疾患治療薬
CN106164089B (zh) 2014-04-02 2020-11-03 日东电工株式会社 靶向分子及其用途
KR102256453B1 (ko) 2014-04-07 2021-05-25 닛토덴코 가부시키가이샤 소수성 약물 전달용 신규한 폴리머계 하이드로트로프
US10092891B2 (en) 2014-04-25 2018-10-09 University Of Florida Research Foundation, Incorporated Controlling the activity of growth factors, particularly TGF-β, in vivo
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
CN109862914A (zh) * 2016-09-30 2019-06-07 中央研究院 微核糖核酸let-7及转化生长因子β第三类受体调控轴作为心脏损伤靶标的用途
EP3771464A1 (de) * 2019-07-31 2021-02-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide als inhibitoren der fibrotischen matrixakkumulation
EP3996694A1 (de) * 2019-07-31 2022-05-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide als inhibitoren der fibrotischen matrixakkumulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) * 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5384309A (en) * 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors

Also Published As

Publication number Publication date
EP0775742A2 (de) 1997-05-28
FI921353A7 (fi) 1992-03-27
DE69030956T2 (de) 1998-01-15
EP0494264B1 (de) 1997-06-18
NO921119L (no) 1992-03-20
FI921353A0 (fi) 1992-03-27
AU6612590A (en) 1991-04-28
DK0494264T3 (da) 1998-01-26
AU654938B2 (en) 1994-12-01
CA2065860C (en) 2001-03-27
NO921119D0 (no) 1992-03-20
CA2065860A1 (en) 1991-03-30
EP0494264A1 (de) 1992-07-15
JPH05503076A (ja) 1993-05-27
FI921353L (fi) 1992-03-27
DE69030956D1 (de) 1997-07-24
WO1991004748A1 (en) 1991-04-18
EP0775742A3 (de) 1998-01-14
JPH0780780B2 (ja) 1995-08-30

Similar Documents

Publication Publication Date Title
DE69030956D1 (de) Inhibierung des transformierenden wachstumsfaktor zur verhinderung der anhäufung extrazellulärer matrix
ES2114065T3 (es) Metodo para el diagnostico y control de la sepsis.
DE3853236D1 (de) Apparat und Methode zur Überwachung des Türantriebes und der Fahrt eines Aufzuges.
IT8619684A0 (it) Preparato di acido ialuronico chimicamente modificato e metodo per recuperarlo da tessuti animali.
DE69723429D1 (de) Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE69432395D1 (de) Verfahren und Vorrichtung zur tomographischen Abbildung des Augenhintergrundes mittels optischer Kohärenz
DE3778677D1 (de) Einrichtung und verfahren zur bildsubstrahierung mit verminderung des bewegungsartefakts.
ES2062241T3 (es) Metodo de purificacion de la albumina serica humana.
ATE233787T1 (de) Methode zur behandlung der corticosteroid- induzierten orteopenie
DK450487D0 (da) Apparat til medicinsk behandling med udladninger fra bipolare elektroder
ES510923A0 (es) Procedimiento y su correspondiente aparato para el adormeci-miento de animales de matanza.
NO922573L (no) Fremgangsmaate for aa paavise ben- og andre bindevevsforstyrrelser hos mennesker og dyr
EP0515434A4 (en) Method for treating intestinal diseases
ATE148628T1 (de) 5-methylisoxazol-4-carbonsäure-anilide und 2- hydroxyethyliden-cyanoessigsäure-anilide zur behandlung von augenkrankheiten
ATE326534T1 (de) Methode zur behandlung von muskelkrankheiten
Huxley et al. Striation patterns in active and passive shortening of muscle
DE69723982D1 (de) Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndroms
NO882373L (no) Fremgangsmaate for silicopyrohydrolysebehandling av bruktehall-heroult-elektrolysetanker.
ATE220915T1 (de) Einen basischen fibroblastwachstumsfaktor enthaltende mittel zur behandlung von knochenkrankheiten
Ingvar et al. A direct method for the measurement of cerebral blood-flow
EP0158987A3 (en) Use of gonadoliberin and its antagonists in the treatment of menopause
Galey et al. Spontaneous alternation disturbance after lesions of the ventral mesencephalic tegmentum in the rat
Kirkby Startle responsivity following telencephalic lesions in the rat
Segura et al. Effects of castration on brain electrogram of the female toad Bufo arenarum Hensel
BE869147A (fr) Procede pour eliminer l'attaque des cathodes au niveau de la solution pendant l'electrolyse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties